AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06782958
Drug: 50mg FHND1002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a daily oral dose of FHND1002 granules (50 mg) ,administered in the morning after fasting for at least 10 hours. The dose will be taken with 240 mL of water.
Trial: NCT06782958
Drug: 150 mg FHND1002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a daily oral dose of FHND1002 granules (150 mg), administered in the morning after fasting for at least 10 hours. The dose will be taken with 240 mL of water.
Trial: NCT06785558
Drug: Anticholinergic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overactive bladder group use anticholinergic drug and 1 month later their urinary atp levels calculated again
Trial: NCT06373211
Drug: Immunoglobulins IV (CLAYRIG)
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be treated with cycles of :~- Intravenous (IV) immunoglobulins: 2 g/kg per cycle, over 3 to 5 days (D1 to D3 or D5).~Cycles will be administered every 4 weeks for a total of 3 first cycles
Trial: NCT06373211
Drug: Cyclophosphamide IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be treated with cycles of :~- Cyclophosphamide IV: 1 g on the first day (D1). Cycles will be administered every 4 weeks for a total of 6 cycles
Trial: NCT06373211
Drug: Methylprednisolone IV
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be treated with cycles of :~Methylprednisolone IV: 1 g/day for 3 days (D1 to D3). Cycles will be administered every 4 weeks for a total of 6 cycles
Trial: NCT04745949
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04745949
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT05489276
Drug: TQB2825 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB2825 injection is a bi-specific, humanized antibody against CD3×CD20, with the structure ratio of anti-CD3 to anti-CD20 of 1:2. It has two asymmetric Fab ends and a complete Fc end, and is a natural IgG4 subtype with weak antibody-dependent cell-mediated cytotoxicity or complement dependent cytotoxicityfunction. By bridging CD3 and CD20, TQB2825 injection induces T cell activation to promote T cell proliferation/expansion, promote the formation of cytolytic synapses, and cause cytotoxic T cells to release perforin and granase, thereby killing CD20 positive tumor cells. Therefore, TQB2825 injection is intended for the treatment of CD20 positive hematologic tumors, including but not limited to lymphoma, leukemia and myeloma.
Trial: NCT06788236
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: three times daily
Trial: NCT05586581
Drug: SV2A PET
RxNorm normalized name: Pet Pectillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SV2A PET scan with radiotracer \[11C\]UCB-J for imaging synaptic density in the brain
Trial: NCT05586581
Drug: TSPO PET
RxNorm normalized name: Pet Pectillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TSPO PET scan with radiotracer \[11C\]PBR28 for imaging of neuroimmune status
Trial: NCT06465329
Drug: REGN7075
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT05666310
Drug: Zoledronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Half of study participants will randomly receive zoledronic acid 5 mg intravenous infusion at month 0 with denosumab placebo at month 0 and 6. All forty participants will receive zoledronic acid 5 mg intravenous infusion at month 12.
Trial: NCT04309734
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally, as one or two placebo capsules, depending on the arm.
Trial: NCT05231629
Drug: Dara-VRd induction
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients undergo induction therapy with 6 cycles of daratumumab, bortezomib, lenalidomide and dexamethasone
Trial: NCT04396366
Drug: QBW251
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QBW251, 300 mg, oral use, one capsule, twice daily.
Trial: NCT04396366
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo, 300 mg, oral use, one capsule, twice daily.
Trial: NCT06262477
Drug: BIIB800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm.
Trial: NCT04934748
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Norepinephrine will be infused at a rate sufficient to maintain the intraoperative MAP designated in the underlying GUARDIAN trial.
Trial: NCT06022861
Drug: LY01015
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenouslly (IV) 240mg every 2 weeks (Q2W) during the combined chemotherapy period, thereafter, 480mg every 4 weeks(Q4W) during the maintenance treatment period
Trial: NCT06022861
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenouslly (IV) l 800mg/m2 every 4 weeks (（on Day 1 through Day 5)during the combined chemotherapy period
Trial: NCT06022861
Drug: Opdivo®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenouslly (IV) 240mg every 2 weeks (Q2W) during the combined chemotherapy period, 480mg every 4 weeks(Q4W) during the maintenance treatment period within 24 weeks, thereafter converted to LY01015 480mg every 4 weeks(Q4W).
Trial: NCT04805606
Drug: CKD-843-R
RxNorm normalized name: R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QD, PO
Trial: NCT04824092
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.
Trial: NCT04824092
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.
Trial: NCT06625489
Drug: Part A: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered.
Trial: NCT06625489
Drug: GSK3915393
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3915393 will be administered.
Trial: NCT05889182
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Tablets
Trial: NCT06154291
Drug: XON7
RxNorm normalized name: Xon7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The trial intervention (XON7) is a glyco-humanized polyclonal antibody drug which is formulated for intravenous (IV) administration
Trial: NCT04997317
Drug: 177Lu-DOTA-JR11 (Phase 0); Cycle 1 and Cycle 2 (cross-over)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 177Lu-DOTA-JR11 has three main components, namely the somatostatin analogue JR11, the chemical chelator group DOTA and the beta emitter 177Lutetium (177Lu). In the Phase 0 part of the study 177Lu-DOTA-JR11 will be administered once intravenously. The activity of the first 2 cycles will be capped at 4.5 GBq (range: 4.2-4.6 GBq).
Trial: NCT04997317
Drug: 177Lu-DOTATOC (Phase 0); Cycle 1 and Cycle 2 (cross-over), Cycle 3 and 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 177Lu-DOTATOC is a therapeutic medicinal product and has 3 main components (a) 177Lutetium (177Lu), a beta-emitting radionuclide with a half-life of 6.64 days; (b) DOTA, a chemical chelator group; and (c) TOC (= \[Tyr\]3-octreotide) an agonistic somatostatin analogue which binds to sstr2 and sstr5 receptors. In the Phase 0 part of the study 177Lu-DOTATOC will be administered once intravenously. The activity of the first 2 cycles will be capped at 4.5 GBq (range: 4.2-4.6 GBq). The remaining 2 cycles will be performed with an activity of 7.4 GBq 177Lu-DOTATOC (total number of cycles = 4).
Trial: NCT06475352
Drug: FOLFOX regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin will be administered at a fixed dose of 85 mg/m² by 2h intravenous (IV) infusion concurrently with folinic acid 400 mg/m² (or 200 mg/m² if L-folinic acid) as a 2 h IV infusion on day 1 of each 14-day cycle followed by 5-fluorouracil (5-FU) 400 mg/m² IV bolus on day 1, then continuous IV infusion of 1,200 mg/m² /day × 2 days (total 2400 mg/m² for 46-48 hours)
Trial: NCT06475352
Drug: CAPOX regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin will be administered at a fixed dose of 130 mg/m² by 2h IV infusion on day 1 of each 21-day cycle followed by capecitabine (1000 mg/m²) twice a day (BID) during 2 weeks, every 3 weeks
Trial: NCT05712460
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for sisunatovir
Trial: NCT04742634
Drug: DEC-C
RxNorm normalized name: Dec-Chlorphen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * DEC-C will be provided by Taiho Pharmaceuticals.~* Cycle 1 Day 1 may take place between Day 42 \& Day 100 post-transplant.
Trial: NCT06785727
Drug: Statin (atorvastatin, fluvastatin, pravastatin, rosuvastatin or simvastatin)
RxNorm normalized name: Nystatin
DrugBank: Nystatin (DB00646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The intervention group receives statin treatment following the current Herseninfarct en Hersenbloeding guideline. The intensity and target value of statin treatment are determined according to this national guideline. Which statin (atorvastatin, fluvastatin, pravastatin, rosuvastatin, simvastatin) will be selected and what dose will be prescribed is left to the discretion of the treating neurologist. The statins are registered in the Netherlands and use will be according to the licenses of the products. They will be collected at the local pharmacy by the patient (following practice as usual).
Trial: NCT06790082
Drug: [68Ga]Ga-FAPI-46 PET/CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with suspected pleural mesothelioma undergo FAPI PET/CT in addition to conventional imaging at primary staging.~The subgroup of patients undergoing anticancer treatment will undergo an additional FAPI PET/CT and FDG PET/CT after completing 2-3 series of anticancer treatment.
Trial: NCT06499844
Drug: Acetylcholine
RxNorm normalized name: Acetylcholine
DrugBank: Acetylcholine (DB03128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: acetylcholine, and acetylcholine + L-NAME (Nitric oxide synthase inhibitor) are locally and acutely delivered to the cutaneous microvasculature to assess endothelium- and nitric oxide-dependent dilation
Trial: NCT05108428
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 825 mg/m\^2 twice daily orally 5 days per week on days of planned radiation therapy.
Trial: NCT05108428
Drug: FOLFOX regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of Care FOLFOX regimen consists of 8 cycles (each cycle is 14 days) of 5-fluorouracil, leucovorin, and oxaliplatin. Dosage is as follows: Oxaliplatin 85 mg/m\^2 IV over 2 hours day 1 each cycle. Leucovorin (optional) 400 mg/m\^2 IV over 2 hours day 1 each cycle. 5-fluorouracil bolus\* (optional) 400 mg/m\^2 IV push day 1 of each cycle, and 5-fluorouracil infusion 2400 mg/m\^2 IV continuous infusion over 46 hours day 1 each cycle.
Trial: NCT04938882
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Before the induction of anesthesia, normal saline is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
Trial: NCT05368766
Drug: Diuretic Effect
RxNorm normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Response to diuretic therapy
Trial: NCT04536181
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12 weeks prednisolone treatment
Trial: NCT04536181
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 weeks simulated tablets
Trial: NCT05387278
Drug: EV-Pure™ and WJ-Pure™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The treatment consists of administration of WJ-Pure™ and EV-Pure™ plus standard care
Trial: NCT05387278
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cryopreservation media plus standard care
Trial: NCT05138653
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to CVL-354
Trial: NCT05093270
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally as a tablet
Trial: NCT05735327
Drug: No intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As this is an observational study, no intervention will be administered.
Trial: NCT05954312
Drug: VVD-130037
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets
Trial: NCT05331144
Drug: Angiotensin II Receptor Blockers (ARBs, losartan) and Calcium Channel Blockers (CCB, amlodipine)
RxNorm normalized name: Angiotensin II receptor blockers (ARBs) and calcium channel blockers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin II Receptor Blockers (ARBs, losartan) and Calcium Channel Blockers (CCB, amlodipine) will be used to treat high blood pressure. Additional antihypertensive medications may be used if needed.
Trial: NCT05523089
Drug: Saline placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile normal saline for injection
Trial: NCT06590012
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will take the placebo capsules in addition to standard treatment for a year.
Trial: NCT06590012
Drug: Tertinat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will take Tertinat capsules in addition to standard treatment for a year.
Trial: NCT06789588
Drug: pharmacogenetic algorithm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dose predictor algorithm proposed in this work aims to maintain and quality treatment in an individualized and effective manner. In the routine use protocol, warfarin is prescribed based only on the INR collected within 5 days. The proposed intervention protocol is based on the patient's clinical and genetic factors, such as genetic polymorphisms, age, weight, height, race, use of amiodarone, statins, antifungals or antibiotics, tobacco use, clinical indication and what the RNI target.
Trial: NCT06789588
Drug: Clinical treatment
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with AF indicated for OAC therapy guided by institutional protocol.
Trial: NCT05635461
Drug: CVN424
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg of either tablet or suspension formulation
Trial: NCT06788171
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine: 1000mg/m2, d1-14, bid, q3w, 6 cycles.
Trial: NCT05306041
Drug: Endocrine therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine therapy per physician´s choice with either tamoxifen 20mg or an aromatase inhibitor +/- GnRH analogue for premenopausal women and men
Trial: NCT06791005
Drug: Preoperative Injection of Carbon Nanoparticles
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.Medication: Carbon nanoparticles, Chongqing Lemay Pharmaceutical Co. Ltd., production license, Food and Drug Administration Production License No. (China) 2007204, Registration No.: State prescription H20041829. The product is a stable suspension of carbon particles with a diameter of 150 nm.2. 2.Preoperative injection method: The preoperative subgroup was injected with carbon nanoparticles 2-6 hours before surgery, with the patient in the position of padded shoulder, and disinfection around the puncture point was prepared prior to the injection of carbon nanoparticles. Under ultrasound guidance, a fine needle was used to puncture the lower 1/3 of the ventral surface, and no blood was detected on aspiration, i.e., 0.1 mL of carbon nanoparticles was injected into each of the 2 sites of each gland, and the total volume of carbon nanoparticles injected was 0.4 mL, and the depth of injection was approximately within the upper third of the gland.
Trial: NCT06791005
Drug: Intraoperative Injection of Carbon Nanoparticles
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative injection of carbon nanoparticles: After exposing the thyroid peritoneum, 0.1 mL of carbon nanoparticles was injected into both sides of normal thyroid tissue using a syringe (1 mL). Two spots were needed for each flap, and the total volume of injected carbon nanoparticles was 0.4 mL. Finally, the needle was gently backed up under negative pressure to prevent the leakage of carbon nanoparticles.
Trial: NCT06523088
Drug: PN20
RxNorm normalized name: Lipram-PN20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Six dose levels of PN20 will be evaluated
Trial: NCT06523088
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of PN20
Trial: NCT04193982
Drug: Combination drug
RxNorm normalized name: combination drugs used in erectile dysfunction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient receives Vitamine E 400mg twice daily and Saraglitazar 4 mg once daily for 6 months
Trial: NCT06215716
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by subcutaneous injection
Trial: NCT05139316
Drug: Oral corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants who receive DTX401 solution will receive oral corticosteroids
Trial: NCT05139316
Drug: Placebo for oral corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants who receive Placebo will receive placebo oral corticosteroids to maintain the study blind
Trial: NCT05593328
Drug: FOLFIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFIRI (irinotecan + fluorouracil \[5-FU\] + leucovorin) as intravenous (IV) infusion
Trial: NCT06223659
Drug: Eutectic Mixture of Local Anesthetics
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply topically to skin
Trial: NCT05503043
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients are received equal volumes of saline intravenously until the end of the surgery
Trial: NCT04898023
Drug: zinc-green tea extract-ascorbic acid
RxNorm normalized name: green tea extract
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compounded capsules containing each zinc citrate, green tea extract, and ascorbic acid.
Trial: NCT05814016
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching danavorexton IV infusion.
Trial: NCT04957485
Drug: Smallpox and Mpox Vaccine
RxNorm normalized name: smallpox and mpox vaccine, live, nonreplicating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vaccine
Trial: NCT05804279
Drug: BPDO-1603
FDA approved: no
EMA approved: no
PMDA approved: no
Description: donepezil/mematine
Trial: NCT05587361
Drug: Placebo Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Patch, no active ingredients
Trial: NCT05792540
Drug: Fluoxetine 20 mg
RxNorm normalized name: fluoxetine 20 MG
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine is a type of antidepressant known as a selective serotonin reuptake inhibitor (SSRI). It's often used to treat depression, and sometimes obsessive-compulsive disorder and bulimia. It works by increasing the levels of serotonin in the brain
Trial: NCT04915365
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (oral capsules, identically looking as active drug), starting dose 3 capsules, subsequent doses~1 capsule in the morning, 2 capsules in the evening, administered in qualifying participants, during the stay at 3100 m.
Trial: NCT05949801
Drug: Neucardin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 days IV infusion of 0.6 ug/kg/day
Trial: NCT05949801
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 days IV infusion of 0 ug/kg/day
Trial: NCT05534165
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: identical placebo 600 mg po BID
Trial: NCT06075771
Drug: Carbidopa Levodopa
RxNorm normalized name: carbidopa / levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive between one and three tablets per day of 150 mg L-DOPA (administered with 37.5 mg carbidopa) to achieve doses ranging from 150 to 450 mg/day.
Trial: NCT06075771
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A placebo is a sugar pill that has no therapeutic effect and will be administered orally. Participants will receive between one and three placebo tablets per day matching the Carbidopa Levodopa tablet.
Trial: NCT00367822
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06750341
Drug: QLC7401
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QLC7401 combined with lipid-lowering agents
Trial: NCT06750341
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo combined with lipid-lowering agents